Vaxcyte Inc (PCVX)

$46.33 -1.03 (-2.17%)
Market Cap 6.84B
Revenue (ttm) 0.00
Net Income (ttm) -766.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,341,200
Avg Vol 1,426,596
Day's Range N/A - N/A
Shares Out 144.40M
Stochastic %K 13%
Beta 1.24
Analysts Strong Sell
Price Target $109.00

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 0111
Website: vaxcyte.com
Address:
825 Industrial Road, Suite 300, San Carlos, United States
KY3000
KY3000 Jun. 4 at 7:04 PM
$PCVX sleeping giant
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 3:55 AM
$PCVX Share Price: $47.42 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $17.59 – $21.73 Target Zone: $31.84 – $38.91 Potential Upside: 71% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AIBioScanner
AIBioScanner May. 25 at 6:25 AM
$PCVX AI-Based Findings on PCVX After running PCVX through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. PCVX is trading around $47.30, below both the 20-day (~$53.65) and 50-day (~$56.44) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-2.85) — bearish momentum • Range between ~$47.17 support and ~$62.76 resistance 1-Month Outlook: Base scenario: consolidation near $44.94–$49.66 Breakout above $49.66 could open a move toward $58.11 Breakdown below $44.94 may extend further downside toward $36.85 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.
0 · Reply
KY3000
KY3000 May. 20 at 5:49 PM
$PCVX $ freeing up soon, MF
0 · Reply
CapitalMonk
CapitalMonk May. 13 at 4:32 AM
$PCVX Price: $54.03 (+0.07%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.40% RSI: 31.6 | Momentum: Strong Downside Volume: -12.8% vs avg Volatility: 3.07% Support: $48.49 | Resistance: $63.31 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
cubie
cubie May. 12 at 4:29 PM
$PCVX yea interesting
0 · Reply
RandyRanderson1
RandyRanderson1 May. 12 at 4:00 PM
@cubie $PCVX Any thoughts on the options trading going on here? Looks like the same trader active across the Oct and Dec. Thanks!
1 · Reply
NorthStarStats
NorthStarStats Apr. 1 at 1:45 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $CSX Score 100, $NUVL Score 100, $AZN Score 100, $WAB Score 100, $PCVX Score 98
0 · Reply
greensmell
greensmell Mar. 7 at 4:42 AM
$PCVX $MRNA https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3?mod=e2tw
0 · Reply
KY3000
KY3000 Mar. 7 at 12:02 AM
$PCVX HMPV, no vaccine can treat it, this should be their next target
0 · Reply
Latest News on PCVX
Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 5 days ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026

Vaxcyte doses first participant in VAX-A1 study

2026-06-02T20:28:55.000Z - 6 days ago

Vaxcyte doses first participant in VAX-A1 study

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Jun 2, 2026, 4:05 PM EDT - 6 days ago

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Vaxcyte Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 6 days ago

Vaxcyte Slides: Corporate presentation

Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 4:40 PM EDT - 27 days ago

Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026

Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)

2026-05-07T01:27:16.000Z - 4 weeks ago

Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:05 PM EDT - 4 weeks ago

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Vaxcyte Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 4 weeks ago

Vaxcyte Quarterly report: Q1 2026

Vaxcyte Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 4 weeks ago

Vaxcyte Earnings release: Q1 2026

Vaxcyte Slides: Corporate presentation

May 5, 2026, 6:00 PM EDT - 4 weeks ago

Vaxcyte Slides: Corporate presentation

Vaxcyte Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Vaxcyte Proxy statement: Proxy filing

Vaxcyte Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Vaxcyte Proxy statement: Proxy filing

Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 2:15 PM EDT - 7 weeks ago

Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 4:05 PM EDT - 2 months ago

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial

2026-03-23T13:06:31.000Z - 2 months ago

Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Mar 23, 2026, 8:30 AM EDT - 2 months ago

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Slides: Corporate presentation

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Vaxcyte Slides: Corporate presentation

Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet

2026-03-18T23:45:17.000Z - 2 months ago

Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Mar 18, 2026, 7:34 PM EDT - 2 months ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Vaxcyte Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:00 PM EDT - 3 months ago

Vaxcyte Transcript: Leerink Global Healthcare Conference 2026

Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 3 months ago

Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference

Vaxcyte price target raised to $89 from $85 at BTIG

2026-02-26T01:15:13.000Z - 3 months ago

Vaxcyte price target raised to $89 from $85 at BTIG

Vaxcyte price target lowered to $133 from $134 at BofA

2026-02-25T15:10:32.000Z - 3 months ago

Vaxcyte price target lowered to $133 from $134 at BofA

Vaxcyte price target raised to $67 from $38 at Goldman Sachs

2026-02-25T13:06:55.000Z - 3 months ago

Vaxcyte price target raised to $67 from $38 at Goldman Sachs

Vaxcyte price target raised to $75 from $50 at TD Cowen

2026-02-25T12:50:02.000Z - 3 months ago

Vaxcyte price target raised to $75 from $50 at TD Cowen

Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year

2026-02-24T21:38:10.000Z - 3 months ago

Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year

Vaxcyte Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

Vaxcyte Earnings Call Transcript: Q4 2025

Vaxcyte Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

Vaxcyte Annual report: Q4 2025

Vaxcyte Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

Vaxcyte Earnings release: Q4 2025

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026, 4:05 PM EST - 3 months ago

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vaxcyte Slides: Corporate presentation

Feb 24, 2026, 4:00 PM EST - 3 months ago

Vaxcyte Slides: Corporate presentation

Vaxcyte Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 1:30 PM EST - 4 months ago

Vaxcyte Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Vaxcyte doses first participants in OPUS-3 trial

2026-02-11T21:30:50.000Z - 4 months ago

Vaxcyte doses first participants in OPUS-3 trial

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Feb 11, 2026, 4:05 PM EST - 4 months ago

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Vaxcyte Slides: Corporate presentation

Feb 11, 2026, 7:00 AM EST - 4 months ago

Vaxcyte Slides: Corporate presentation

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Feb 10, 2026, 4:05 PM EST - 4 months ago

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

Feb 5, 2026, 4:05 PM EST - 4 months ago

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 2, 2026, 4:05 PM EST - 4 months ago

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte 11M share Spot Secondary priced at $50.00

2026-01-30T11:06:07.000Z - 4 months ago

Vaxcyte 11M share Spot Secondary priced at $50.00

Vaxcyte Announces Pricing of $550 Million Public Offering

Jan 29, 2026, 11:33 PM EST - 4 months ago

Vaxcyte Announces Pricing of $550 Million Public Offering

Vaxcyte secondary being re-offered at $50 per share

2026-01-30T00:45:09.000Z - 4 months ago

Vaxcyte secondary being re-offered at $50 per share

Vaxcyte offering marketed at $50 per share, Bloomberg says

2026-01-29T22:55:17.000Z - 4 months ago

Vaxcyte offering marketed at $50 per share, Bloomberg says

Vaxcyte announces offering of $500M of common stock and warrants

2026-01-29T21:11:25.000Z - 4 months ago

Vaxcyte announces offering of $500M of common stock and warrants

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 29, 2026, 4:06 PM EST - 4 months ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte provides update on development of VAX-31 pneumococcal vaccine

2026-01-22T22:10:28.000Z - 4 months ago

Vaxcyte provides update on development of VAX-31 pneumococcal vaccine

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Jan 22, 2026, 5:00 PM EST - 4 months ago

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Needham ups Vaxcyte target, adds to Conviction List

2026-01-07T11:20:26.000Z - 5 months ago

Needham ups Vaxcyte target, adds to Conviction List

PHAT

Mizuho positive on Vaxcyte after HHS maintains PCV schedule for children

2026-01-05T20:30:12.000Z - 5 months ago

Mizuho positive on Vaxcyte after HHS maintains PCV schedule for children

This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.

Dec 22, 2025, 8:19 AM EST - 6 months ago

This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.

Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31

2025-12-08T12:05:20.000Z - 6 months ago

Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Dec 8, 2025, 7:00 AM EST - 6 months ago

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 1:20 PM EST - 6 months ago

Vaxcyte Transcript: Evercore ISI 8th Annual HealthCONx Conference

Vaxcyte Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:30 AM EST - 7 months ago

Vaxcyte Transcript: Jefferies London Healthcare Conference 2025

Vaxcyte Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 2:30 PM EST - 7 months ago

Vaxcyte Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)

2025-11-04T21:20:25.000Z - 7 months ago

Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Nov 4, 2025, 4:05 PM EST - 7 months ago

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Vaxcyte Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 7 months ago

Vaxcyte Slides: Corporate Presentation

Vaxcyte Earnings release: Q3 2025

Nov 4, 2025, 7:00 AM EST - 7 months ago

Vaxcyte Earnings release: Q3 2025

Vaxcyte Quarterly report: Q3 2025

Nov 4, 2025, 7:00 AM EST - 7 months ago

Vaxcyte Quarterly report: Q3 2025

Vaxcyte price target lowered to $85 from $160 at BTIG

2025-10-16T11:45:29.000Z - 8 months ago

Vaxcyte price target lowered to $85 from $160 at BTIG

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

Vaxcyte Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 9 months ago

Vaxcyte Transcript: Cantor Global Healthcare Conference 2025

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

Sep 3, 2025, 7:30 AM EDT - 9 months ago

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Vaxcyte Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Vaxcyte Quarterly report: Q2 2025

Vaxcyte Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Vaxcyte Earnings release: Q2 2025

Vaxcyte Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 1:20 PM EDT - 1 year ago

Vaxcyte Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Vaxcyte Transcript: Jefferies Global Life Sciences Conference

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Vaxcyte Transcript: Jefferies Global Life Sciences Conference

Vaxcyte Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference 2025

Vaxcyte Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 11:40 AM EDT - 1 year ago

Vaxcyte Transcript: BofA Securities 2025 Healthcare Conference

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:01 PM EDT - 1 year ago

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Earnings release: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Vaxcyte Earnings release: Q1 2025

Vaxcyte Quarterly report: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Vaxcyte Quarterly report: Q1 2025

Vaxcyte Slides: Investor Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

Vaxcyte Slides: Investor Presentation

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Vaxcyte Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Proxy statement: Proxy Filing

Vaxcyte Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Proxy statement: Proxy Filing

Vaxcyte Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Proxy statement: Proxy Filing

Vaxcyte Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 1:30 PM EDT - 1 year ago

Vaxcyte Transcript: 24th Annual Needham Virtual Healthcare Conference

Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 1 year ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI

Vaxcyte Transcript: Study Result

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Transcript: Study Result

Vaxcyte Press release: Study Result

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Press release: Study Result

Vaxcyte Slides: Study Result

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Slides: Study Result

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Mar 30, 2025, 5:00 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Vaxcyte Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 2:20 PM EDT - 1 year ago

Vaxcyte Transcript: Leerink’s Global Healthcare Conference 2025

Vaxcyte Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:50 PM EST - 1 year ago

Vaxcyte Transcript: TD Cowen 45th Annual Healthcare Conference

Vaxcyte Earnings Call Transcript: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Earnings Call Transcript: Q4 2024

Vaxcyte Annual report: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Annual report: Q4 2024

Vaxcyte Earnings release: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Earnings release: Q4 2024

Vaxcyte Slides: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Slides: Q4 2024

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 4:01 PM EST - 1 year ago

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Vaxcyte Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

Vaxcyte Transcript: Guggenheim SMID Cap Biotech Conference

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Feb 5, 2025, 8:00 AM EST - 1 year ago

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 4:05 PM EST - 1 year ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 30, 2025, 11:51 AM EST - 1 year ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Vaxcyte Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 12:30 PM EST - 1 year ago

Vaxcyte Transcript: 7th Annual Evercore ISI HealthCONx Conference

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Dec 3, 2024, 8:00 AM EST - 1 year ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 5:00 AM EST - 1 year ago

Vaxcyte Transcript: Jefferies London Healthcare Conference 2024

Vaxcyte Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 1:30 PM EST - 1 year ago

Vaxcyte Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Nov 12, 2024, 7:30 AM EST - 1 year ago

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte Quarterly report: Q3 2024

Nov 5, 2024, 4:00 PM EST - 1 year ago

Vaxcyte Quarterly report: Q3 2024

Vaxcyte Earnings release: Q3 2024

Nov 5, 2024, 4:00 PM EST - 1 year ago

Vaxcyte Earnings release: Q3 2024

Vaxcyte Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 10:20 AM EDT - 1 year ago

Vaxcyte Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Sep 6, 2024, 9:07 AM EDT - 1 year ago

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Sep 5, 2024, 1:22 AM EDT - 1 year ago

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 4, 2024, 11:58 PM EDT - 1 year ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Sep 3, 2024, 10:48 AM EDT - 1 year ago

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Sep 3, 2024, 10:10 AM EDT - 1 year ago

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Sep 3, 2024, 9:24 AM EDT - 1 year ago

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Sep 3, 2024, 8:51 AM EDT - 1 year ago

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Vaxcyte Transcript: Study Result

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Vaxcyte Transcript: Study Result

Vaxcyte Slides: Study Result

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Vaxcyte Slides: Study Result

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 3, 2024, 7:07 AM EDT - 1 year ago

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 2, 2024, 6:40 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Vaxcyte Quarterly report: Q2 2024

Vaxcyte Earnings release: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Vaxcyte Earnings release: Q2 2024

Vaxcyte Appoints John Furey to Board of Directors

Jul 2, 2024, 8:30 AM EDT - 2 years ago

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference

Vaxcyte Transcript: Bank of America Health Care Conference 2024

May 14, 2024, 12:20 PM EDT - 2 years ago

Vaxcyte Transcript: Bank of America Health Care Conference 2024

Vaxcyte Slides: Investor Presentation

May 10, 2024, 2:00 PM EDT - 2 years ago

Vaxcyte Slides: Investor Presentation

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:05 PM EDT - 2 years ago

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Vaxcyte Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Vaxcyte Quarterly report: Q1 2024

Vaxcyte Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Vaxcyte Earnings release: Q1 2024

Vaxcyte Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Vaxcyte Proxy statement: Proxy Filing

Vaxcyte Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Vaxcyte Proxy statement: Proxy Filing

Vaxcyte Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 12:45 PM EDT - 2 years ago

Vaxcyte Transcript: 23rd Annual Needham Virtual Healthcare Conference

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 4:05 PM EDT - 2 years ago

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Vaxcyte Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 8:40 AM EDT - 2 years ago

Vaxcyte Transcript: Leerink Partners Global Biopharma Conference 2024

Vaxcyte Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 5, 2024, 2:10 PM EST - 2 years ago

Vaxcyte Transcript: TD Cowen 44th Annual Health Care Conference 2024

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Mar 4, 2024, 8:30 AM EST - 2 years ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Vaxcyte Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Vaxcyte Earnings Call Transcript: Q4 2023

Vaxcyte Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Vaxcyte Annual report: Q4 2023

Vaxcyte Earnings release: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Vaxcyte Earnings release: Q4 2023

Vaxcyte Slides: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Vaxcyte Slides: Q4 2023

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 4:01 PM EST - 2 years ago

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 15, 2024, 4:05 PM EST - 2 years ago

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

KY3000
KY3000 Jun. 4 at 7:04 PM
$PCVX sleeping giant
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 3:55 AM
$PCVX Share Price: $47.42 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $17.59 – $21.73 Target Zone: $31.84 – $38.91 Potential Upside: 71% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AIBioScanner
AIBioScanner May. 25 at 6:25 AM
$PCVX AI-Based Findings on PCVX After running PCVX through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. PCVX is trading around $47.30, below both the 20-day (~$53.65) and 50-day (~$56.44) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-2.85) — bearish momentum • Range between ~$47.17 support and ~$62.76 resistance 1-Month Outlook: Base scenario: consolidation near $44.94–$49.66 Breakout above $49.66 could open a move toward $58.11 Breakdown below $44.94 may extend further downside toward $36.85 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.
0 · Reply
KY3000
KY3000 May. 20 at 5:49 PM
$PCVX $ freeing up soon, MF
0 · Reply
CapitalMonk
CapitalMonk May. 13 at 4:32 AM
$PCVX Price: $54.03 (+0.07%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.40% RSI: 31.6 | Momentum: Strong Downside Volume: -12.8% vs avg Volatility: 3.07% Support: $48.49 | Resistance: $63.31 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
cubie
cubie May. 12 at 4:29 PM
$PCVX yea interesting
0 · Reply
RandyRanderson1
RandyRanderson1 May. 12 at 4:00 PM
@cubie $PCVX Any thoughts on the options trading going on here? Looks like the same trader active across the Oct and Dec. Thanks!
1 · Reply
NorthStarStats
NorthStarStats Apr. 1 at 1:45 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $CSX Score 100, $NUVL Score 100, $AZN Score 100, $WAB Score 100, $PCVX Score 98
0 · Reply
greensmell
greensmell Mar. 7 at 4:42 AM
$PCVX $MRNA https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3?mod=e2tw
0 · Reply
KY3000
KY3000 Mar. 7 at 12:02 AM
$PCVX HMPV, no vaccine can treat it, this should be their next target
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 2:34 AM
$PCVX Current Stock Price: $61.97 Contracts to trade: $60.0 PCVX Mar 20 2026 Call Entry: $3.90 Exit: $7.48 ROI: 92% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
KY3000
KY3000 Feb. 28 at 7:14 PM
$PCVX don’t worry about production
0 · Reply
KY3000
KY3000 Feb. 25 at 10:34 PM
$PCVX needs to announce another target, they going to be commercialized sooner than later
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 9 at 7:17 PM
$PCVX Share Price: $55.51 Contract Selected: Jul 17, 2026 $55 Calls Buy Zone: $6.54 – $8.09 Target Zone: $11.59 – $14.16 Potential Upside: 67% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BuffettStyleInvestments
BuffettStyleInvestments Feb. 4 at 11:54 AM
$PCVX is a vaccine developer with a promising pneumococcal candidate; its valuation is binary on phase 3 data and potential market disruption of entrenched players.
0 · Reply
CC01
CC01 Jan. 30 at 6:10 PM
$PCVX Strong buy
0 · Reply
KY3000
KY3000 Jan. 23 at 3:17 PM
$STRO if you believe in $PCVX, than 300$ mill in milestones is a lock
0 · Reply